Login
$MBX
$53.12 -$2.82 (5.04%) Live

$MBX SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Hoerter Steven L., Director

Sold 4,893 shares ($268K)

10 Nov 2026 144
10 Nov 2026 S-8
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway

05 Nov 2026 Form 4: Azoulay Salomon, Chief Medical Officer

Sold 373 shares ($20.1K)

05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 144
22 Oct 2026 Form 4: Radovich Peter, Director

Granted 18,200 Stock option (right to buy)

22 Oct 2026 Form 3: Radovich Peter, Director

No securities owned

22 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed P...

27 Aug 2026 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

17 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 SCHEDULE 13D/A
10 Aug 2026 SCHEDULE 13D/A
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting

05 Aug 2026 Form 4: Azoulay Salomon, Chief Medical Officer

Sold 370 shares ($24.3K)

04 Aug 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support